EGFR and non-small cell lung carcinoma: In addition, in the subgroup analysis of the IMpower 150 trial, atezolizumab plus bevacizumab plus carboplatin plus paclitaxel therapy significantly benefited patients with EGFR-mutated NSCLC in both PFS and OS [28].